Clinical Trial Update: 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms [Phase 3]

View source ↗

Summary

Phase 3 24-week efficacy and safety study of Brisdelle (paroxetine mesylate) for vasomotor symptoms due to menopause; results from the completed trial have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause

Drugs mentioned

• Brisdelle (paroxetine mesylate)

Snippet

Sponsor: Noven Therapeutics | Conditions: Hot Flashes | Phase 3 | Status: COMPLETED | Results posted: 2014-04-21